Advertisement Allied-Bristol Life Sciences licenses Yale University's platform technology and lead molecules - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Allied-Bristol Life Sciences licenses Yale University’s platform technology and lead molecules

Allied-Bristol Life Sciences (ABLS) has entered into a worldwide licensing agreement with Yale University for a proprietary platform technology and associated lead molecules to further developed new treatments for diseases such as prostate cancer.

The proprietary synthetic molecules called Antibody Recruiting Molecules (ARMs) are developed by professor David Spiegel and his team at Yale University.

The ARMs work by harnessing the power of the body’s own immune system to treat cancer.

They carry out this process by recruiting antibodies already present in the bloodstream and then leading these antibodies to a specific protein found on the surface of cancer cells and from there, the antibodies perform their natural immune function of destroying the diseased cells.

ABLS is a biopharmaceutical enterprise jointly owned between Allied Minds (ALM.L) and Bristol-Myers Squibb Company (BMY).

ABLS chief executive officer Satish Jindal said: "Dr Spiegel’s ARM approach presents a differentiated solution that has strong potential to develop next-generation oncology drugs with improved safety and efficacy.

"We are eager to work with David and Yale on this program. This innovative university technology and associated lead molecules are at the ideal stage that we are seeking, where we can bring to bear the drug discovery and development expertise of ABLS and its partners to accelerate therapies to the clinic."

The new licensing agreement with Yale is the second in a series of discovery and development projects that ABLS intends to pursue.

The license to the technology will be held by a new ABLS subsidiary that was specifically formed to complete further research and pre-clinical characterization of a specific set of molecules based on the technology so that a clinical candidate can be advanced.